PharmAust Intellectual Property Update

2018-2019

5th March 2019 – Perth, Australia: PharmAust (ASX: PAA), a clinical-stage oncology company, has received "Notices of Allowance" and "Notices to Grant" for a number of its patent applications relating to MPL (monepantel), from various territories and jurisdictions during 2018 and 2019. These patents pertain to both "Composition of Matter" in relation to new MPL analogues (structurally similar entities to MPL) as well as to "Methods of Use" of MPL and its analogues in cancer and other diseases. The catalogue of recent patents now comprises:

Patent No./ Patent Application No.	Field of Cover	Status	Country	Date of Allowance/ Grant
2016204389	MPL for Treatment of Cancer	Granted	Australia	10/05/2018
2868120	MPL for Treatment of Cancer	Allowed	Canada	9/11/2018
201610041111.6	MPL Analogues for Treatment of Cancer	Allowed	China	28/01/2019
2817286	MPL for Treatment of Cancer	Granted	Europe	6/06/2018
16162192.5	MPL Analogues for Treatment of Cancer	Allowed	Europe	22/11/2018
2017-36116	MPL Analogues for Treatment of Cancer	Allowed	Japan	21/01/2019
HK1205502	Compounds for the treatment of mTOR pathway related diseases	Granted	Hong Kong	20/04/2018
6441219	Compounds for the treatment of mTOR pathway related diseases	Granted	Japan	30/11/2018
10,053,422	Compounds for the treatment of mTOR pathway related diseases with Analogues	Granted	United States of America	21/08/2018
14781682.1	Anticancer agent comprising aminoacetonitrile compound as active ingredient (MPL Analogues)	Allowed	Europe	14/12/2018
9,907,778	Anticancer agent comprising aminoacetonitrile compound as active ingredient (MPL Analogues)	Granted	United States of America	6/03/2018
15/878057	Anticancer agent comprising aminoacetonitrile compound as active ingredient (MPL Analogues)	Allowed	United States of America	15/01/2019

To protect its intellectual property (IP) and know-how, PharmAust has maintained an active program of patenting MPL for cancer, as well as for other diseases and disorders reliant on mTOR pathway and also for MPL analogues for which the potency may be greater or more selective. The research and development relating to MPL was undertaken with NewSouth

Innovations (NSi), the commercialisation arm of the University of New South Wales. PharmAust has now secured assignments to all IP from NSi in relation to the above.

Dr Roger Aston, PharmAust's Chairman commented, "We are delighted with the outcome of our patent applications which will serve us well in our negotiations with prospective licensees. Filing and maintenance of intellectual property is a key aspect of drug discovery and development and allows small companies to carve out the use of particular drugs for various diseases and territories. We are grateful to NSi for its contribution."

Enquiries:

Dr Roger Aston
Executive Chairman and CEO
Tel: 0402 762 204
rogeraston@pharmaust.com

Dr Richard Mollard
Chief Scientific Officer
Tel: 0418 367 855
rmollard@pharmaust.com

About PharmAust (PAA):
PAA is a clinical-stage company developing therapeutics for both humans and animals. The company specialises in repurposing marketed drugs lowering the risks and costs of development. These efforts are supported by PAA's subsidiary, Epichem, a highly successful contract medicinal chemistry company which generated ~Aus$3.02m in revenues in the 2018 FY.